Recent Business Highlights

Biologics: Creating substantial value in long term from new portfolio choices while driving R&D productivity 6 commercial products; > 50 filings across 14 major countries FY20 Product Portfolio FY20 Business Profile 5 new products in clinical development Strong and relevant play in Emerging Markets Developed Markets Royalties expected to Kick-in FY25 Business Profile Emerging Markets Revenue: $300 Mn - $400Mn Developed Markets Profits: > $100Mn EBITDA margin post R&D: > 35 % 21

View entire presentation